⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284258 | 0.76 | — | — | |
| SCHEMBL20011629 | 0.73 | — | — | |
| SCHEMBL12569970 | 0.73 | — | — | |
| Water SCHEMBL28075677 | 0.73 | — | — | |
| SCHEMBL12569748 | 0.73 | — | — | |
| SCHEMBL1544138 | 0.71 | — | — | |
| SCHEMBL458484 | 0.67 | — | — | |
| SCHEMBL18985736 | 0.67 | — | — | |
| SCHEMBL19668286 | 0.67 | — | — | |
| SCHEMBL17236155 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9371316-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371316-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1638962-A2 | SUBSTITUTED OXYARENES UND DEREN VERWENDUNG ZUR BEKÄMPFUNG VON SCHÄDLINGEN | Bayer CropScience AG (DE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-12 | — | — | US | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| WO-2005080397-A2 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004099197-A2 | SUBSTITUTED OXYARENES, AND USE THEREOF FOR CONTROLLING PESTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-11-18 | — | — | WO | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |